Blood Test for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to detect multiple myeloma, a type of blood cancer, at its early stage known as MGUS (monoclonal gammopathy of undetermined significance) to improve long-term health outcomes. It involves two groups: those with MGUS and smoldering multiple myeloma, and those with other plasma cell disorders. Individuals who identify as Black or African American, are 30 or older, and live in or near Charlotte, NC, might be a good fit. Participants should not have a history of certain plasma cell disorders.
As an unphased trial, this study offers a unique opportunity to contribute to early detection strategies and potentially improve future health outcomes for others.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about the CHAAMP Internal Pilot Study because it aims to understand more about plasma cell disorders such as MGUS (monoclonal gammopathy of undetermined significance) and smoldering multiple myeloma, particularly in the African American population. Unlike treatments, this trial focuses on gathering data to improve early detection and risk stratification for these conditions. By identifying specific genetic or environmental factors affecting these disorders, the study could lead to more personalized approaches in the future. This could potentially fill the gap in knowledge about why African Americans might experience these conditions differently, ultimately leading to better-targeted interventions and outcomes.
Who Is on the Research Team?
Manisha Bhutani, MD
Principal Investigator
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Evaluation
Participants screening positive for monoclonal gammopathy are referred for further diagnostic evaluation to confirm MGUS, SMM, or other PCD-related disorder
Longitudinal Follow-up
Participants diagnosed with MGUS and smoldering multiple myeloma are prospectively followed for 10 years
What Are the Treatments Tested in This Trial?
Interventions
- Blood draw
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants diagnosed with other plasma cell disorders
Participants diagnosed with MGUS and smoldering multiple myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Atrium Health Levine Cancer Institute
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.